Baby-OSCAR - Outcome after Selective Early Treatment for Closure of Patent Ductus ARteriosus in Pre-term Babies
- Principal investigator
- Samir Gupta (University Hospital of North Tees, Stockton-on-Tees)
- Collaborators
- Jonathan Wyllie (South Tees Hospitals NHS Foundation Trust), Nim Subhedar (Liverpool Women's NHS Foundation Trust), Sunil Sinha (South Tees Hospitals NHS Foundation Trust), Tracy Roberts (University of Birmingham), Justine Pepperell (Bliss (charity for babies born too soon, too small, too sick - PPI), London), Wilf Kelsall (Cambridge University Hospitals NHS Foundation Trust), Samantha Johnson (University of Nottingham), Elizabeth Hutchison (Patient and Public representative), David Field (University of Leicester), Pollyanna Hardy (NPEU (Former member)), Ed Juszczak (NPEU)
- Topics
- Care of the preterm or low birthweight infant
- Funder
- National Institute for Health Research Health Technology Assessment Programme
- Start year
- 2021
- End year
- 2014
- NPEU Contact
- Marketa Laube
Summary
The Baby-OSCAR clinical trial is a multicentre randomised placebo-controlled trial of ibuprofen treatment for significant patent ductus arteriosus in preterm infants. The aim is to find out whether or not a confirmed large Patent Ductus Arteriosus (PDA) in very premature babies should be treated with ibuprofen within 72 hours of birth.
The internal pilot phase (assessing the practicalities of trial procedures, the equipoise of clinicians and the willingness of parents to enrol their infants into the study) was successful and ended in December 2015 - the main recruitment phase will roll out to all sites just as soon as drug and matched placebo have been sourced, packaged and released.
Publications
Journal Articles